.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Novartis
McKinsey
Johnson and Johnson
US Department of Justice
Teva
Daiichi Sankyo
Cerilliant
AstraZeneca
Harvard Business School

Generated: September 23, 2017

DrugPatentWatch Database Preview

VIMPAT Drug Profile

« Back to Dashboard

What is the patent landscape for Vimpat, and what generic Vimpat alternatives are available?

Vimpat is a drug marketed by Ucb Inc and is included in three NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has nineteen patent family members in eleven countries.

The generic ingredient in VIMPAT is lacosamide. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the lacosamide profile page.

Summary for Tradename: VIMPAT

Patents:1
Applicants:1
NDAs:3
Suppliers / Packagers: see list3
Bulk Api Vendors: see list61
Clinical Trials: see list47
Patent Applications: see list545
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIMPAT at DailyMed

Pharmacology for Tradename: VIMPAT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
VIMPAT
lacosamide
SOLUTION;ORAL022255-001Apr 20, 2010AARXYesYes► Subscribe► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-001Oct 28, 2008ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-004Oct 28, 2008ABRXYesYes► Subscribe► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-002Oct 28, 2008ABRXYesNo► Subscribe► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-004Oct 28, 2008ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Ucb Inc
VIMPAT
lacosamide
SOLUTION;INTRAVENOUS022254-001Oct 28, 2008RXYesYes► Subscribe► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
SOLUTION;INTRAVENOUS022254-001Oct 28, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-001Oct 28, 2008ABRXYesNo► Subscribe► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-002Oct 28, 2008ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Ucb Inc
VIMPAT
lacosamide
SOLUTION;ORAL022255-001Apr 20, 2010AARXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIMPAT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-003Oct 28, 2008► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-004Oct 28, 2008► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-001Oct 28, 2008► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
SOLUTION;INTRAVENOUS022254-001Oct 28, 2008► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
SOLUTION;ORAL022255-001Apr 20, 2010► Subscribe► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-002Oct 28, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VIMPAT

Drugname Dosage Strength RLD Submissiondate
lacosamide Injection10 mg/mL, 20 mLVimpat 6/30/2016
lacosamideOral Solution10 mg/mLVimpat10/29/2012
lacosamideTablets50 mg, 100 mg, 150 mg, and 200 mgVimpat10/29/2012

Non-Orange Book Patents for Tradename: VIMPAT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,773,475 Anticonvulsant enantiomeric amino acid derivatives► Subscribe
6,048,899 Anticonvulsant enantiomeric amino acid derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIMPAT

Country Document Number Estimated Expiration
Canada2248317► Subscribe
Portugal888289► Subscribe
Australia2539497► Subscribe
Germany69729392► Subscribe
Japan2000505476► Subscribe
Spain2218024► Subscribe
Denmark0888289► Subscribe
European Patent Office1038522► Subscribe
Austria202079► Subscribe
Germany69705210► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIMPAT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C001/2009Ireland► SubscribeSPC001/2009: 20091013, EXPIRES: 20220316
C/GB09/007United Kingdom► SubscribePRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829
0888289/01Switzerland► SubscribePRODUCT NAME: LACOSAMIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 59004 28.08.2009
2009 00001Denmark► Subscribe
00376Netherlands► SubscribePRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE: EU/1/08/470/001-016 20080829
C0006France► SubscribePRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Dow
Baxter
Argus Health
Citi
Cerilliant
AstraZeneca
US Army
Accenture
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot